Insulet Corporation (NASDAQ:PODD) Receives $240.78 Average Target Price from Analysts

Insulet Corporation (NASDAQ:PODD) has been given a consensus recommendation of “Moderate Buy” by the twenty-eight brokerages that are presently covering the firm, MarketBeat Ratings reports. Two analysts have rated the stock with a sell rating, four have given a hold rating and twenty-two have assigned a buy rating to the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $238.6667.

PODD has been the topic of several analyst reports. Benchmark reissued a “buy” rating on shares of Insulet in a report on Wednesday, May 27th. Royal Bank Of Canada restated an “outperform” rating and set a $280.00 price objective on shares of Insulet in a research report on Wednesday, May 27th. Jefferies Financial Group dropped their price objective on Insulet from $400.00 to $360.00 in a research report on Thursday, May 7th. Sanford C. Bernstein dropped their price objective on Insulet from $330.00 to $200.00 and set an “outperform” rating for the company in a research report on Thursday, May 7th. Finally, Citigroup dropped their price objective on Insulet from $175.00 to $165.00 and set a “neutral” rating for the company in a research report on Thursday, May 28th.

Insulet Stock Up 2.9%

PODD opened at $158.25 on Monday. Insulet has a 1-year low of $138.79 and a 1-year high of $354.88. The stock’s fifty day simple moving average is $159.09 and its 200 day simple moving average is $220.64. The company has a current ratio of 2.49, a quick ratio of 1.81 and a debt-to-equity ratio of 0.71. The stock has a market cap of $10.96 billion, a PE ratio of 36.80, a price-to-earnings-growth ratio of 1.07 and a beta of 1.13.

Insulet (NASDAQ:PODD) last posted its quarterly earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share for the quarter, beating analysts’ consensus estimates of $1.19 by $0.23. Insulet had a return on equity of 26.87% and a net margin of 10.44%.The business had revenue of $761.70 million for the quarter, compared to analysts’ expectations of $729.89 million. During the same quarter in the prior year, the business earned $1.02 EPS. The firm’s revenue for the quarter was up 33.9% on a year-over-year basis. Insulet has set its FY 2026 guidance at 6.210- EPS. As a group, research analysts expect that Insulet will post 6.46 earnings per share for the current year.

Insider Buying and Selling at Insulet

In other Insulet news, Director Timothy C. Stonesifer acquired 2,790 shares of the company’s stock in a transaction that occurred on Wednesday, June 3rd. The stock was acquired at an average cost of $143.51 per share, for a total transaction of $400,392.90. Following the transaction, the director directly owned 9,041 shares in the company, valued at $1,297,473.91. This represents a 44.63% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. 0.36% of the stock is currently owned by corporate insiders.

Institutional Trading of Insulet

Several institutional investors and hedge funds have recently modified their holdings of the business. Norges Bank bought a new position in Insulet in the fourth quarter valued at about $300,794,000. Arrowstreet Capital Limited Partnership raised its position in Insulet by 462.7% in the first quarter. Arrowstreet Capital Limited Partnership now owns 1,229,928 shares of the medical instruments supplier’s stock valued at $258,088,000 after purchasing an additional 1,011,369 shares during the last quarter. RTW Investments LP bought a new position in Insulet in the fourth quarter valued at about $92,264,000. AQR Capital Management LLC raised its position in Insulet by 161.6% in the fourth quarter. AQR Capital Management LLC now owns 459,115 shares of the medical instruments supplier’s stock valued at $130,499,000 after purchasing an additional 283,643 shares during the last quarter. Finally, SG Americas Securities LLC raised its position in Insulet by 712.1% in the first quarter. SG Americas Securities LLC now owns 318,848 shares of the medical instruments supplier’s stock valued at $66,907,000 after purchasing an additional 279,587 shares during the last quarter.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.